Johnson and Johnson said a combination therapy containing the company’s blockbuster cancer drug Imbruvica significantly improved survival in blood cancer patients, compared with drugs currently used as the standard of care.
Nearly 40 percent of lymphoma patients treated with a single infusion of Gilead Sciences Inc.’s Yescarta were still responding to the cell therapy after at least two years of follow-up.
Swiss pharma giant Novartis announced plans to seek regulatory approval for 60 new treatments between 2019 and 2021.
AbbVie and Roche’s targeted therapy delayed the progression of a type of blood and bone marrow cancer when used in combination with the Swiss drugmaker’s cancer drug in a late-stage trial.
Shares of Verastem climbed following U.S. regulatory approval for the leukemia drug Copiktra, an inhibitor of phosphoinositide 3-kinase-delta and PI3K-gamma.
AbbVie, a research-based global biopharmaceutical company, announced that the Phase 3 iLLUMINATE (PCYC-1130) trial met its primary endpoint of improvement in progression-free survival.
Pfizer Inc. announced that REFLECTIONS B3281006, a comparative safety and efficacy study of PF-05280586 versus MabThera (rituximab-EU), met its primary endpoint.
The DUO study showed statistically significant PFS improvement for duvelisib versus standard of care treatment ofatumumab.
Patients with a type of leukemia that had relapsed who received the new drug Venclexta in combination with Rituxan went significantly longer without the disease worsening than those treated with Rituxan and Treanda, according to interim results from a pivotal late-stage study released on Tuesday.
The U.S. regulatory agency approved Genentech’s Gazyva for patients with previously untreated advanced follicular lymphoma.